Department of Medicine, University of Salamanca, Spain.
BMC Cancer. 2010 Aug 24;10:454. doi: 10.1186/1471-2407-10-454.
Gliomas are the most common type of primary brain tumours, and in this group glioblastomas (GBMs) are the higher-grade gliomas with fast progression and unfortunate prognosis. Two major aspects of glioma biology that contributes to its awful prognosis are the formation of new blood vessels through the process of angiogenesis and the invasion of glioma cells. Despite of advances, two-year survival for GBM patients with optimal therapy is less than 30%. Even in those patients with low-grade gliomas, that imply a moderately good prognosis, treatment is almost never curative. Recent studies have demonstrated the existence of a small fraction of glioma cells with characteristics of neural stem cells which are able to grow in vitro forming neurospheres and that can be isolated in vivo using surface markers such as CD133. The aim of this study was to define the molecular signature of GBM cells expressing CD133 in comparison with non expressing CD133 cells. This molecular classification could lead to the finding of new potential therapeutic targets for the rationale treatment of high grade GBM.
Eight fresh, primary and non cultured GBMs were used in order to study the gene expression signatures from its CD133 positive and negative populations isolated by FACS-sorting. Dataset was generated with Affymetrix U133 Plus 2 arrays and analysed using the software of the Affymetrix Expression Console. In addition, genomic analysis of these tumours was carried out by CGH arrays, FISH studies and MLPA;
Gene expression analysis of CD133+ vs. CD133- cell population from each tumour showed that CD133+ cells presented common characteristics in all glioblastoma samples (up-regulation of genes involved in angiogenesis, permeability and down-regulation of genes implicated in cell assembly, neural cell organization and neurological disorders). Furthermore, unsupervised clustering of gene expression led us to distinguish between two groups of samples: those discriminated by tumour location and, the most importantly, the group discriminated by their proliferative potential;
Primary glioblastomas could be sub-classified according to the properties of their CD133+ cells. The molecular characterization of these potential stem cell populations could be critical to find new therapeutic targets and to develop an effective therapy for these tumours with very dismal prognosis.
神经胶质瘤是最常见的原发性脑肿瘤,在该组中,胶质母细胞瘤(GBM)是高级别胶质瘤,具有快速进展和不良预后。神经胶质瘤生物学的两个主要方面促成了其糟糕的预后,一是通过血管生成过程形成新的血管,二是神经胶质瘤细胞的侵袭。尽管取得了进展,但接受最佳治疗的 GBM 患者的两年生存率仍低于 30%。即使对于那些预后较好的低级别神经胶质瘤患者,治疗也几乎无法治愈。最近的研究表明,存在一小部分具有神经干细胞特征的神经胶质瘤细胞,这些细胞能够在体外生长形成神经球,并可以通过表面标志物(如 CD133)在体内分离。本研究的目的是确定表达 CD133 的 GBM 细胞与不表达 CD133 的细胞相比的分子特征。这种分子分类可能会为高级别 GBM 的合理治疗找到新的潜在治疗靶点。
使用 8 例新鲜、未经培养的原发性 GBM 来研究通过 FACS 分选分离的 CD133 阳性和阴性细胞群体的基因表达特征。使用 Affymetrix U133 Plus 2 芯片生成数据集,并使用 Affymetrix Expression Console 软件进行分析。此外,还通过 CGH 芯片、FISH 研究和 MLPA 对这些肿瘤进行基因组分析;
对每个肿瘤的 CD133+与 CD133-细胞群体的基因表达分析表明,CD133+细胞在所有 GBM 样本中表现出共同特征(参与血管生成、通透性的基因上调,以及参与细胞组装、神经细胞组织和神经紊乱的基因下调)。此外,基因表达的无监督聚类使我们能够区分两组样本:一组由肿瘤位置区分,最重要的是,另一组由其增殖潜力区分;
原发性胶质母细胞瘤可以根据其 CD133+细胞的特性进行亚分类。这些潜在的干细胞群体的分子特征对于寻找新的治疗靶点和为这些预后极差的肿瘤开发有效的治疗方法可能至关重要。